Viking Therapeutics Inc

NASDAQ:VKTX   10:40:38 AM EDT
5.69
-0.08 (-1.39%)
Products, Regulatory, Other Pre-Announcement

Viking Therapeutics Announces Results From Phase 1 Clinical Trial Of Novel Oral Thyroid Receptor Beta Agonist Vk0214

Published: 06/17/2021 12:15 GMT
Viking Therapeutics Inc (VKTX) - Viking Therapeutics Announces Results From Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist Vk0214.
Viking Therapeutics Inc - Statistically Significant Reductions Observed for Key Lipids, Including Ldl Cholesterol, Triglycerides and Apolipoprotein B.
Viking Therapeutics Inc - Phase 1b Study in X-ald Patients to Be Initiated in Coming Weeks.
Viking Therapeutics - First-in-human Clinical Trial of Novel, Selective Thyroid Receptor Beta Agonist Demonstrates Encouraging Safety and Tolerability.
Viking Therapeutics Inc - Expects to Initiate a Phase 1b Study of Vk0214 in Patients With X-ald in Coming Weeks.